NEW YORK, June 4 – Isis Pharmaceuticals has appointed Richard Brown to lead its GeneTrove functional genomics division, the company said Monday.
Brown, formerly president of Irori, the technology and instrumentation division of Discovery Partners International, a combinatorial chemistry company, will oversee all scientific and business operations of the division, including the launch of the GeneTrove Gene Function Database later this year.
Prior to serving as president of Irori, Brown spent 13 years at Zymark, a manufacturer of automated laboratory equipment, and three years at Jarrell-Ash, a spectrometer maker now part of Thermo Jarrell-Ash.
“Rick's primary objective is to run GeneTrove as a highly competitive business and make it the premier entry in the functional genomics arena,” Isis CEO Stanley Crooke said in a statement. “By combining his commercialization experience with the quality and efficiency of GeneTrove's antisense approach to gene target validation, we believe GeneTrove is well-positioned to be the functional genomics service of choice."
Isis’ GeneTrove division focuses on using antisense technology to provide functional genomics services for pharmaceutical customers. On May 25, Isis and Hybridon signed a $40 million cross-licensing deal that consolidated control of antisense technology between the two companies. In addition, Isis is involved in drug discovery, with one HIV-related drug on the market and two in late-stage development.